DE60234085D1 - Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor - Google Patents
Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitorInfo
- Publication number
- DE60234085D1 DE60234085D1 DE60234085T DE60234085T DE60234085D1 DE 60234085 D1 DE60234085 D1 DE 60234085D1 DE 60234085 T DE60234085 T DE 60234085T DE 60234085 T DE60234085 T DE 60234085T DE 60234085 D1 DE60234085 D1 DE 60234085D1
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- compound interferon
- recombinant super
- antigen inhibitor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011043679A CN1245215C (zh) | 2001-02-28 | 2001-02-28 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
PCT/CN2002/000128 WO2002080958A1 (fr) | 2001-02-28 | 2002-02-28 | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60234085D1 true DE60234085D1 (de) | 2009-12-03 |
Family
ID=4653854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60234085T Expired - Lifetime DE60234085D1 (de) | 2001-02-28 | 2002-02-28 | Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor |
Country Status (10)
Country | Link |
---|---|
US (3) | US7364724B2 (de) |
EP (1) | EP1371373B1 (de) |
JP (1) | JP4617058B2 (de) |
CN (1) | CN1245215C (de) |
AT (1) | ATE446104T1 (de) |
AU (1) | AU2003248419B2 (de) |
CA (1) | CA2439503A1 (de) |
DE (1) | DE60234085D1 (de) |
HK (1) | HK1061201A1 (de) |
WO (1) | WO2002080958A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US20050079579A1 (en) * | 2001-02-28 | 2005-04-14 | Guangwen Wei | Uses of spatial configuration to modulate protein function |
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
ATE531803T1 (de) * | 2003-06-05 | 2011-11-15 | Ajinomoto Kk | Fermentierungsverfahren mittels veränderter bakterien mit einer erhöhten aufnahme von nebenprodukten |
CA2535902A1 (en) * | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
CN102294020A (zh) * | 2003-08-28 | 2011-12-28 | 辉阳科技美国公司 | 空间构象改变的干扰素及其应用 |
AU2011202683B2 (en) * | 2003-08-28 | 2012-08-09 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
CN1740197B (zh) * | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
WO2006134497A2 (en) * | 2005-03-09 | 2006-12-21 | Guangwen Wei | Uses of recombinant super-compound interferons |
CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
CN102101886A (zh) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
WO2013055811A1 (en) * | 2011-10-12 | 2013-04-18 | Hitachi Chemical Co., Ltd. | Ex vivo methods of predicting responsiveness of a subject to interferon therapy |
SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
EP2583680A3 (de) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Einzel- (PSI-7977) oder Kombinationsbehandlung in der Verwendung zur Behandlung von HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
TWI670494B (zh) | 2013-11-13 | 2019-09-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
EP3294321B1 (de) | 2015-05-12 | 2024-07-31 | Superlab Far East Limited | Verfahren zur bestimmung von interferon mit direkten hemmungsauswirkungen auf tumoren und verwendungen davon |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
NZ202698A (en) | 1981-12-07 | 1986-02-21 | Hoffmann La Roche | Human leukocyte interferon in crystalline form |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4681930A (en) | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
DE4329756A1 (de) | 1993-09-03 | 1995-03-09 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
EP0626448A3 (de) | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
DE69636195T2 (de) | 1995-10-13 | 2007-03-29 | President And Fellows Of Harvard College, Cambridge | Phosphopantethenyltransferasen und deren verwendungen |
US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US6532437B1 (en) | 1996-10-23 | 2003-03-11 | Cornell Research Foundation, Inc. | Crystalline frap complex |
CN1186120A (zh) | 1996-12-24 | 1998-07-01 | 深圳科兴生物制品有限公司 | 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白 |
AU1619699A (en) * | 1997-12-05 | 1999-06-28 | Human Genome Sciences, Inc. | Synferon, a synthetic type i interferon |
US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
KR20010024899A (ko) | 1998-02-06 | 2001-03-26 | 일렉서스 피티와이 리미티드 | Fc 수용체의 삼차원 구조 및 모델 및 그의 용도 |
CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
KR100399156B1 (ko) | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
CN1175901C (zh) | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
US7544354B2 (en) * | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
EP1355939A2 (de) | 2000-11-03 | 2003-10-29 | Pestka Biomedical Laboratories, Inc. | Interferone, deren verwendungen und zusammensetzungen |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US6546074B1 (en) | 2001-03-27 | 2003-04-08 | Astex Technology Limited | Protein crystal structure and method for identifying protein modulators |
CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
US6807478B2 (en) * | 2001-12-27 | 2004-10-19 | Koninklijke Philips Electronics N.V. | In-building navigation system |
CN1176946C (zh) | 2002-05-16 | 2004-11-24 | 中国人民解放军第二军医大学 | 一种新型α干扰素 |
CN1202861C (zh) | 2003-07-18 | 2005-05-25 | 中国科学院微生物研究所 | 复合干扰素在治疗sars疾病中的用途 |
CA2535902A1 (en) | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
WO2006134497A2 (en) | 2005-03-09 | 2006-12-21 | Guangwen Wei | Uses of recombinant super-compound interferons |
-
2001
- 2001-02-28 CN CNB011043679A patent/CN1245215C/zh not_active Expired - Lifetime
-
2002
- 2002-02-28 EP EP02702211A patent/EP1371373B1/de not_active Expired - Lifetime
- 2002-02-28 WO PCT/CN2002/000128 patent/WO2002080958A1/zh active Application Filing
- 2002-02-28 CA CA002439503A patent/CA2439503A1/en not_active Abandoned
- 2002-02-28 DE DE60234085T patent/DE60234085D1/de not_active Expired - Lifetime
- 2002-02-28 AT AT02702211T patent/ATE446104T1/de not_active IP Right Cessation
- 2002-02-28 JP JP2002578997A patent/JP4617058B2/ja not_active Expired - Lifetime
-
2003
- 2003-08-28 US US10/650,365 patent/US7364724B2/en not_active Expired - Lifetime
- 2003-09-26 AU AU2003248419A patent/AU2003248419B2/en not_active Expired
-
2004
- 2004-06-15 HK HK04104296.9A patent/HK1061201A1/xx not_active IP Right Cessation
-
2008
- 2008-04-18 US US12/105,455 patent/US8114395B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,044 patent/US8425896B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US8425896B2 (en) | 2013-04-23 |
CN1245215C (zh) | 2006-03-15 |
AU2003248419B2 (en) | 2007-01-04 |
EP1371373A1 (de) | 2003-12-17 |
HK1061201A1 (en) | 2004-09-10 |
US20040202641A1 (en) | 2004-10-14 |
ATE446104T1 (de) | 2009-11-15 |
EP1371373B1 (de) | 2009-10-21 |
CN1311035A (zh) | 2001-09-05 |
US7364724B2 (en) | 2008-04-29 |
JP4617058B2 (ja) | 2011-01-19 |
EP1371373A4 (de) | 2005-05-04 |
US20110189128A1 (en) | 2011-08-04 |
JP2005508848A (ja) | 2005-04-07 |
US20080305080A1 (en) | 2008-12-11 |
AU2003248419A1 (en) | 2003-11-06 |
US8114395B2 (en) | 2012-02-14 |
WO2002080958A1 (fr) | 2002-10-17 |
CA2439503A1 (en) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60234085D1 (de) | Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor | |
ES2523837T3 (es) | Agentes de unión específica al factor de crecimiento de hepatocitos | |
ATE405647T1 (de) | Rekombinantes gelatin in impstoffen | |
DK1476541T3 (da) | Cytokin (zcytor17-ligand) | |
FR20C1016I1 (de) | ||
DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
DK1406656T3 (da) | Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer | |
DK1261723T3 (da) | Hybrid ekspression af Neisseria-proteiner | |
ATE390441T1 (de) | Niedrigallergene proteinvarianten | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
DE60138014D1 (de) | Chimäre arterivirus-ähnliche partikel | |
CY1111750T1 (el) | Νευροτροφικοι παραγοντες | |
CY2010008I1 (el) | Αντισωματα αντι-tnf, συνθεσεις, μεθοδοι και χρησεις | |
LU92748I2 (fr) | Virus de la diarrhée virale bovine atténué 2 (bvdv-2) | |
DE60207053D1 (de) | Rekombinante gelatineartige proteine zur verwendung als plasmaexpander | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
DK1362109T3 (da) | Rekombinante oligomere protein-komplekser med foröget immunogent potentiale | |
ATE313558T1 (de) | Reinigung von hbv-antigenen zur verwendung in impfstoffen | |
NO20042173L (no) | Fremgangsmate for fremstilling av rekombinant polypeptid | |
DK1501936T3 (da) | Familie af cytokin-proteiner | |
ATA192799A (de) | Neue verwendung von antikörpern als impfstoffe | |
ATE473997T1 (de) | Zur bildung von partikeln fähiges hbv-precore- protein | |
DE60115938D1 (de) | Monoklonale antikörper gegen hepatitis b virus | |
DE60026666D1 (de) | Induktion von antigen-spezifischen T-Zellen durch Interferon | |
EP1310512A3 (de) | HCV-Kernprotein-Sequenzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |